Baron Funds Comments on Bristol-Myers Squibb Company
After initiating a position in Bristol-Myers Squibb Company ( BMY ), we increased our conviction in BMY's stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 8…-85% market share versus Merck's competitive asset Keytruda, while growing -…--…% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat -…-6's $-.- billion Consensus sales number. Looking past -…-6, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin's lymphoma, etc.) and helps change the paradigm of cancer's treatment worldwide.
Warning! GuruFocus has detected 1 Warning Sign with AL. Click here to check it out.
Warning! GuruFocus has detected 6 Warning Sign with IRM. Click here to check it out.
Warning! GuruFocus has detected 6 Warning Sign with IRM. Click here to check it out.
Warning! GuruFocus has detected 7 Warning Signs with BMY. Click here to check it out.
From Baron Opportunity Fund first quarter -…-6 commentary .
Read More:
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.